Second Primary Cancer Risk among Kidney Cancer Patients in Korea: A Population-Based Cohort Study

키워드

참고문헌 (42)

1. Travis LB, "The epidemiology of second primary cancers", Cancer Epidemiol Biomarkers Prev, 15, pp.2020~2026 (2006)[DOI]
2. Wood ME, "Second malignant neoplasms: assessment and strategies for risk reduction", J Clin Oncol, 30, pp.3734~3745 (2012)[DOI]
3. Ljungberg B, "Renal cell carcinoma guideline", Eur Urol, 51, pp.1502~1510 (2007)[DOI]
4. 오창모, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013", Cancer Research and Treatment, 48(2), pp.436~450 (2016), 대한암학회
5. Chen T, "Risk of subsequent cancers in renal cell carcinoma survivors with a family history", Eur J Cancer, 50, pp.2108~2118 (2014)[DOI]
6. Liu H, "Renal cell carcinoma as first and second primary cancer: etiological clues from the Swedish Family-Cancer Database", J Urol, 185, pp.2045~2049 (2011)[DOI]
7. Hemminki K, "Multiple primary cancers as clues to environmental and heritable causes of cancer and mechanisms of carcinogenesis", IARC Sci Publ, (157), pp.289~297 (2004)
8. Travis LB, "Cancer survivorship: genetic susceptibility and second primary cancers: research strategies and recommendations", J Natl Cancer Inst, 98, pp.15~25 (2006)[DOI]
9. Rixe O, "Renal cell carcinoma: ten years of significant advances", Target Oncol, 5, pp.73~74 (2010)[DOI]
10. Rini BI, "Renal cell carcinoma", Curr Opin Oncol, 18, pp.289~296 (2006)[DOI]
11. Hai-Rim Shin, "Nationwide Cancer Incidence in Korea, 1999~2001; First Result Using the National Cancer Incidence Database", Cancer Research and Treatment, 37(6), pp.325~331 (2005), 대한암학회
12. Curado MP, "Cancer incidence in five continents. Vol. 9" (2007), IARC Press
13. Fritz A, "International classification of diseases for oncology. 3rd ed." (2000)
14. Cho YY, "Elevated risks of subsequent primary malignancies in patients with thyroid cancer: a nationwide, population-based study in Korea", Cancer, 121, pp.259~268 (2015)[DOI]
15. International Agency for Research on Cancer, "International rules for multiple primary cancers (ICD-O third edition)" (2004)
16. Curtis RE, "New malignancies among cancer survivors: SEER cancer registries, 1973-2000. NIH Publ. No. 05-5302" (2006)
17. Esteve J, "Statistical methods in cancer research. Vol. IV. Descriptive epidemiology. IARC scentific publication. No. 128" (1994)
18. Tsugane S, "Salt, salted food intake, and risk of gastric cancer: epidemiologic evidence", Cancer Sci, 96, pp.1~6 (2005)[DOI]
19. Tsugane S, "Salt and salted food intake and subsequent risk of gastric cancer among middle-aged Japanese men and women", Br J Cancer, 90, pp.128~134 (2004)[DOI]
20. Chakraborty S, "Incidence and prognostic significance of second primary cancers in renal cell carcinoma", Am J Clin Oncol, 36, pp.132~142 (2013)[DOI]
21. Beisland C, "Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study", BJU Int, 97, pp.698~702 (2006)[DOI]
22. Rabbani F, "Second primary malignancies associated with renal cell carcinoma: influence of histologic type", Urology, 56, pp.399~403 (2000)[DOI]
23. Thompson RH, "Second primary malignancies associated with renal cell carcinoma histological subtypes", J Urol, 176, pp.900~903 (2006)[DOI]
24. Sun M, "Treatment of metastatic renal cell carcinoma", Nat Rev Urol, 7, pp.327~338 (2010)[DOI]
25. Mataraza JM, "Recent advances in immuno-oncology and its application to urological cancers", BJU Int, 118, pp.506~514 (2016)[DOI]
26. Davey RJ, "Metastatic melanoma treatment: combining old and new therapies", Crit Rev Oncol Hematol, 98, pp.242~253 (2016)[DOI]
27. Hu-Lieskovan S, "Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma", Sci Transl Med, 7, pp.279ra41~ (2015)[DOI]
28. Massari F, "PD-1 blockade therapy in renal cell carcinoma: current studies and future promises", Cancer Treat Rev, 41, pp.114~121 (2015)[DOI]
29. Mahoney KM, "The next immunecheckpoint inhibitors: PD-1", PD-L1 blockade in melanoma, 2015, pp.37, 764~782
30. Carosella ED, "A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1", PD-L1, and HLA-G, 2015, pp.68, 267~279
31. Rubino C, "Second primary malignancies in thyroid cancer patients", Br J Cancer, 89, pp.1638~1644 (2003)[DOI]
32. Ronckers CM, "Thyroid cancer and multiple primary tumors in the SEER cancer registries", Int J Cancer, 117, pp.281~288 (2005)[DOI]
33. Berthe E, "Risk of second primary cancer following differentiated thyroid cancer", Eur J Nucl Med Mol Imaging, 31, pp.685~691 (2004)[DOI]
34. Edmonds CJ, "The long-term hazards of the treatment of thyroid cancer with radioiodine", Br J Radiol, 59, pp.45~51 (1986)[DOI]
35. Akslen LA, "Second malignancies in thyroid cancer patients: a population-based survey of 3658 cases from Norway", Eur J Cancer, 28, pp.491~495 (1992)[DOI]
36. Malchoff CD, "Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome", J Clin Endocrinol Metab, 85, pp.1758~1764 (2000)
37. Cohen HT, "Renal-cell carcinoma", N Engl J Med, 353, pp.2477~2490 (2005)[DOI]
38. Fioroni I, "Role of c-mesenchymal-epithelial transition pathway in gastric cancer", Expert Opin Pharmacother, 16, pp.1195~1207 (2015)[DOI]
39. Peng Z, "Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis", PLoS One, 9, pp.e84502~ (2014)[DOI]
40. Miettinen M, "Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs): a review", Int J Biochem Cell Biol, 53, pp.514~519 (2014)[DOI]
41. Niemeijer ND, "Succinate dehydrogenase (SDH)-deficient pancreatic neuroendocrine tumor expands the SDHrelated tumor spectrum", J Clin Endocrinol Metab, 100, pp.E1386~E1393 (2015)[DOI]
42. Doyle LA, "Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study", Histopathology, 61, pp.801~809 (2012)[DOI]

관련 논문AI추천